C-reactive Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others), By Detection Range (hs-CRP, Conventional CRP, cCRP), By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others), By End-Use Industry (Hospitals & Clinics, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others), By Region, Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 1601.01 Million

CAGR (2023-2028)

2.16%

Fastest Growing Segment

Immunoturbidimetric Assays

Largest Market

North America


Market Overview

Global C-reactive Protein Testing Market has valued at USD 1601.01 Million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 2.16% through 2028. C-reactive Protein Testing is a laboratory test that measures the level of C-reactive protein in the blood. C-reactive protein is a type of protein that is produced by the liver in response to inflammation in the body. It is part of the body's natural immune response to infection, injury, or other forms of inflammation. CRP testing is typically done through a blood sample, and the results are reported as milligrams of CRP per liter of blood (mg/L). Normal CRP levels are generally low, and elevated levels may indicate ongoing inflammation or infection. However, it's important to note that CRP levels can also be influenced by other factors, such as smoking, obesity, and certain medications. CRP testing is commonly used as a marker of inflammation in various medical settings. It is often ordered by healthcare providers to help diagnose and monitor a wide range of conditions, such as: Infections, Autoimmune Diseases, Cardiovascular Diseases, Trauma or Surgery, Monitoring Treatment.

 Key Market Drivers

Growing Incidence of Inflammatory and Infectious Diseases

The growing incidence of inflammatory and infectious diseases contributes significantly to the growth of the global C-reactive protein (CRP) testing market. Inflammatory and infectious diseases often involve an immune response, which can lead to elevated CRP levels in the bloodstream. As the incidence of these diseases rises, healthcare providers need reliable diagnostic tools to detect and monitor the presence of inflammation. CRP testing offers a convenient and effective way to assess inflammation levels, aiding in the diagnosis and management of various conditions. Timely detection of inflammation is crucial for effective disease management and prevention of complications. CRP testing allows for early identification of inflammation, enabling healthcare professionals to intervene before the condition worsens. This aligns with the broader trend of focusing on preventive healthcare and early disease detection. Many chronic diseases, such as rheumatoid arthritis, inflammatory bowel disease, and certain autoimmune disorders, involve ongoing inflammation. CRP testing helps clinicians monitor the severity of inflammation and adjust treatment plans accordingly. As the prevalence of these chronic conditions increases, the demand for CRP testing as a monitoring tool also grows. Inflammations is a recognized risk factor for cardiovascular diseases (CVD), including heart attacks and strokes. Elevated CRP levels have been associated with increased CVD risk. Healthcare providers use CRP testing as part of an overall risk assessment for CVD, which can influence treatment decisions and lifestyle recommendations. CRP levels can rise in response to infections, both bacterial and viral. Monitoring CRP levels can aid in tracking the progression of infections, evaluating the effectiveness of antimicrobial therapies, and determining when a patient is recovering. The increasing prevalence of inflammatory and infectious diseases has prompted extensive research into the role of inflammation in various health conditions. This research generates insights into the relationship between CRP levels and disease outcomes, further highlighting the importance of CRP testing in clinical practice.

Increasing Awareness of Preventive Healthcare

The increasing awareness of preventive healthcare has a significant impact on driving the growth of the global C-reactive protein (CRP) testing market. Preventive healthcare focuses on identifying health issues at an early stage, even before symptoms become apparent. CRP testing serves as a valuable tool in this context by detecting low-grade inflammation that might not be clinically evident yet. Early detection of inflammation through CRP testing enables timely intervention and management, potentially preventing the progression of underlying diseases. Preventive healthcare often involves assessing an individual's risk of developing certain diseases. CRP testing can contribute to risk stratification by providing information about a person's inflammation levels. Elevated CRP levels are associated with an increased risk of conditions such as cardiovascular diseases, making CRP testing a valuable component of risk assessment protocols. The awareness of preventive healthcare promotes the idea of personalized health plans tailored to an individual's specific risk factors and health needs. CRP testing adds an objective biomarker to guide these personalized plans, helping healthcare providers design interventions and lifestyle modifications that address inflammation-related risks. Preventive healthcare often emphasizes lifestyle modifications to promote better health outcomes. CRP testing results can serve as a tangible marker that motivates individuals to make healthier choices, such as improving their diet, increasing physical activity, and quitting smoking. The availability of CRP testing supports educational efforts aimed at empowering individuals to take control of their health. Public health initiatives and screening programs are a part of preventive healthcare efforts. CRP testing can be integrated into these programs to identify individuals at risk of inflammatory conditions and related diseases. This proactive approach can lead to early interventions, reducing the burden of chronic diseases on healthcare systems.

Increasing Geriatric Population And Associated Chronic Diseases

The increasing geriatric population and the associated prevalence of chronic diseases play a significant role in driving the growth of the global C-reactive protein (CRP) testing market. Aging is associated with changes in the immune system, making older adults more susceptible to inflammation. Chronic low-grade inflammation, known as inflammation, is common in the elderly and contributes to the development of various age-related chronic diseases. CRP testing is a valuable tool to assess and monitor this chronic inflammation, providing insights into disease risk and progression. The geriatric population is more prone to chronic diseases such as cardiovascular diseases, diabetes, osteoarthritis, and certain cancers. CRP testing helps healthcare providers evaluate the inflammatory component of these diseases, aiding in their diagnosis, management, and monitoring. Older adults are at an increased risk of cardiovascular diseases, and inflammation is a key factor in their pathogenesis. CRP testing is used to assess cardiovascular risk and guide treatment decisions, particularly in the elderly population, where preventive measures are crucial. Elderly individuals often have multiple chronic conditions simultaneously. CRP testing provides insights into the overall inflammatory status, helping healthcare providers manage multimorbidity more effectively and make informed treatment choices. Older adults are more susceptible to infections due to age-related changes in the immune system. CRP levels can rise in response to infections, aiding in the assessment and monitoring of infectious diseases, which can have more serious consequences in the elderly. Preventive healthcare in the geriatric population emphasizes early detection and intervention to prevent disease progression and improve quality of life. CRP testing contributes to this approach by detecting inflammation at an early stage, allowing for timely interventions and personalized treatment plans. Geriatric care facilities and long-term care settings often serve individuals with complex health needs. CRP testing is a valuable tool in these settings for monitoring residents' health, identifying potential infections, and managing chronic diseases.

 

Download Free Sample Report

Key Market Challenges

Non-Specificity of Elevated CRP

The non-specificity of elevated C-reactive protein (CRP) levels poses a challenge to the global CRP testing market primarily because it can lead to uncertainties in diagnosis and treatment decisions. Elevated CRP levels indicate the presence of inflammation, but they do not provide specific information about the underlying cause of inflammation. This lack of specificity can lead to diagnostic confusion, as healthcare providers may need to conduct additional tests to pinpoint the exact condition causing the elevated CRP. As a result, there might be delays in diagnosing the actual underlying disease. The non-specific nature of CRP elevation can lead to situations where CRP testing is ordered excessively or inappropriately, contributing to unnecessary healthcare costs and resource utilization. Healthcare providers may order CRP tests in cases where inflammation is present but not clinically significant, potentially leading to overdiagnosis and overuse of healthcare services.

Varied Reference Ranges

Different laboratories and healthcare facilities may use varying reference ranges for defining normal, elevated, and high CRP levels. This inconsistency can lead to confusion among healthcare providers and patients when interpreting CRP test results. A value that is considered normal in one setting might be categorized as elevated in another, affecting clinical decision-making. Varied reference ranges can create uncertainty about whether a given CRP level is within a normal range or indicative of inflammation. This ambiguity can lead to challenges in diagnosing inflammatory conditions accurately, potentially delaying appropriate treatment and management. Efforts to establish standardized reference ranges for CRP levels can help ensure consistent interpretation across different settings and laboratories. Professional medical organizations can provide guidelines and recommendations for interpreting CRP test results and defining reference ranges based on clinical evidence and consensus.

Influence of External Factors

The influence of external factors on C-reactive protein (CRP) levels can pose challenges to the global CRP testing market, affecting the accuracy, interpretation, and clinical utility of CRP test results. CRP levels can be affected by various external factors, such as smoking, obesity, and medications. These factors can lead to elevated CRP levels even in the absence of significant inflammation. Healthcare providers may misinterpret elevated CRP levels as indicative of inflammation when they are actually driven by external influences. When external factors contribute to elevated CRP levels, healthcare providers may face challenges in distinguishing between true inflammation and non-inflammatory causes of CRP elevation. This complexity can lead to difficulties in accurately diagnosing and managing inflammatory conditions. External factors can lead to false positive or false negative CRP test results. For example, a patient with inflammation might have normal CRP levels due to the influence of certain medications. Conversely, a patient with elevated CRP levels due to non-inflammatory factors might be wrongly considered at risk for inflammation-related conditions. External factors can lead to fluctuations in CRP levels over time, even in the absence of changes in disease status. This inconsistency can make it challenging to monitor disease progression accurately and make informed treatment decisions.

Key Market Trends

Rising Demand for Personalized Medicine

The rising demand for personalized medicine is a significant trend in the global C-reactive protein (CRP) testing market, influencing its growth and application. Personalized medicine aims to tailor medical treatment and interventions to individual patients based on their unique characteristics, including genetic makeup, lifestyle, and biomarker profiles. Personalized medicine relies on biomarkers to guide treatment decisions. CRP testing serves as a valuable biomarker for assessing inflammation, which plays a role in various diseases. Healthcare providers use CRP levels to help determine the most appropriate treatment strategies for individual patients. CRP testing contributes to personalized medicine by assessing an individual's risk for certain diseases, such as cardiovascular diseases. Elevated CRP levels can indicate increased risk, prompting healthcare providers to implement preventive measures and lifestyle interventions tailored to the patient's risk profile. In personalized medicine, ongoing monitoring of disease progression is essential. CRP testing provides a means to monitor the level of inflammation over time, enabling healthcare providers to adjust treatment plans based on changes in CRP levels and disease status. Personalized medicine involves monitoring a patient's response to treatment. CRP testing helps healthcare providers gauge the effectiveness of interventions by tracking changes in inflammation levels. If CRP levels decrease, it may indicate a positive response to treatment.

Segmental Insights

Assay Type Insights

In 2022, the C-reactive Protein Testing market was dominated by the immunoturbidimetric assays segment and is predicted to continue expanding over the coming years. Immunoturbidimetric assays are highly accurate and precise, making them ideal for clinical applications. Immunoturbidimetric assays are relatively easy to use, making them suitable for use in a variety of settings, including hospitals, clinics, and diagnostic laboratories. Immunoturbidimetric assays are relatively cost-effective, making them a good option for budget-conscious organizations. In immunoturbidimetric assays, the amount of light scattered by a solution is measured to determine the concentration of an analyte. The segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.

Detection Range Insight

In 2022, the C-reactive Protein Testing market was dominated by hs-CRP 3 segment segment and is predicted to continue expanding over the coming years. hs-CRP 3 assays are more sensitive than conventional CRP assays, which means they can detect lower levels of CRP. This makes them more useful for assessing the risk of cardiovascular disease. hs-CRP 3 assays are widely accepted by clinicians and are used in many clinical guidelines. This makes them a good option for organizations that want to use a validated assay. hs-CRP 3 assays are relatively cost-effective, making them a good option for budget-conscious organizations.

Disease Area Insight

In 2022, the C-reactive Protein Testing market was dominated by cardiovascular diseases (CVD) segment and is predicted to continue expanding over the coming years. CVD is the leading cause of death worldwide. Elevated levels of CRP are associated with an increased risk of developing CVD, such as heart attack and stroke. CRP testing is used to assess the risk of developing CVD in people who are at high risk, such as those with diabetes, high blood pressure, or high cholesterol. CRP testing is also used to monitor the effectiveness of treatment for CVD, such as statins or aspirin.

End-Use Industry Insights

In 2022, the C-reactive Protein Testing market was dominated by hospital segment and is predicted to continue expanding over the coming years. The growth of the hospital segment can be attributed to the growing use of CRP tests in hospitals, especially in developing countries around the world. Due to the increasing prevalence of diseases such as coronavirus, coronary artery disease (CVD), and cancer related infections, the number of hospital admissions has increased, which has led to an increase in the need for CRP test kits.

 

Download Free Sample Report

Regional Insights

The North America region has established itself as the leader in the Global C-reactive Protein Testing Market. With a growing incidence of cardiovascular disease, a consistent flow of product introductions, well-established players in the market, cutting-edge technology, and an established healthcare system.

Recent Developments

  • In September 2022, Roche to acquire biopharma firm Good therapeutics for USD 250 m. Roche’s IL-2 drug business is focused on developing conditionally active drugs based on innovative IL-2 drug technology that are PD-1 regulated. In the context of the acquisition, Roche obtains the rights to an IL-2 drug that is conditionally active and PD-1 regulated, which is called the Good Therapeutic Programme. Roche also obtains the exclusive use of the platform technology developed by Good Therapeutic for the development of IL-2 drug therapy that is PD-1 regulated and receptor agonist therapy.
  • In February 2023, Danaher Corporation Announces the Formation of Veralto Corporation (“Veralto” or the “Company”) Danaher Corporation has announced the formation of a separate public company, Veralto Corporation, which Danaher plans to initiate in the fourth quarters of 2023. Veralto will consist of an impressive portfolio of leading brands in Danaher’s EAS segment, including: Hach ChemTreat Trojan OTC HydroMet McCreter Water Quality Platform Videojet Esko X-rite Pantone Linx Product Identification Platform.
  • In April 2023, Siemens healthineers continues to expand its manufacturing footprint in India, with the inauguration of an MRI facility in Bengaluru under the government of India's PLI scheme.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corp
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Abbott Laboratories Inc.
  • Merck KGaAA
  • Zoetis Inc.
  • Ortho Clinical Diagnostics
  • Getein Biotech, Inc.

 By Assay Type

 By Detection Range

By Region

  By End Use

By Disease Area
  • Immunoturbidimetric Assay
  • ELISA
  • Chemiluminescence Immunoassay
  • Others
  • hs-CRP
  • Conventional CRP
  • cCRP
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • South America
  • Hospitals & Clinics
  • Laboratories
  • Assisted Living Healthcare Facilities
  • Homecare
  • Others
  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Endometriosis
  • Lupus
  • Others

 

 

 

Report Scope:

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • C-reactive Protein Testing Market, By Assay Type:

o   Immunoturbidimetric Assay

o   ELISA

o   Chemiluminescence Immunoassay

o   Others

  • C-reactive Protein Testing Market, By Detection Range:

o   hs-CRP

o   Conventional CRP

o   cCRP

  • C-reactive Protein Testing Market, By Disease Area:

o   Cardiovascular Diseases

o   Cancer

o   Rheumatoid Arthritis

o   Inflammatory Bowel Disease

o   Endometriosis

o   Lupus

o   Others

  • C-reactive Protein Testing Market, By End-User:

o   Hospitals & Clinics

o   Laboratories

o   Assisted Living Healthcare Facilities

o   Homecare

o   Others

  • Global C-reactive Protein Testing Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customizations:

Global C-reactive Protein Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global C-reactive Protein Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global C-reactive Protein Testing Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others)

5.2.2.    By Detection Range (hs-CRP, Conventional CRP, cCRP)

5.2.3.    By Disease Area (Cardiovascular Disease, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others)

5.2.4.    By End-Use Industry (Clinics and Hospitals, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others)

5.2.5.    By Company (2022)

5.2.6.    By Region

5.3.  Market Map

6.    North America C-reactive Protein Testing Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Type

6.2.2.    By End-Use Industry

6.2.3.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States C-reactive Protein Testing Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.            By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.            By Assay Type

6.3.1.2.2.            By Detection Range

6.3.1.2.3.            By Disease Area

6.3.1.2.4.            By End-Use Industry

6.3.2.    Mexico C-reactive Protein Testing Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.            By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.            By Assay Type

6.3.2.2.2.            By Detection Range

6.3.2.2.3.            By Disease Area

6.3.2.2.4.            By End-Use Industry

6.3.3.    Canada C-reactive Protein Testing Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.            By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.            By Assay Type

6.3.3.2.2.            By Detection Range

6.3.3.2.3.            By Disease Area

6.3.3.2.4.            By End-Use Industry

7.    Europe C-reactive Protein Testing Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Type

7.2.2.    By End-Use Industry 

7.2.3.    By Country

7.3.  Europe: Country Analysis

7.3.1.    France C-reactive Protein Testing Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.            By Assay Type

7.3.1.2.2.            By Detection Range

7.3.1.2.3.            By Disease Area

7.3.1.2.4.            By End-Use Industry

7.3.2.    Germany C-reactive Protein Testing Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.            By Assay Type

7.3.2.2.2.            By Detection Range

7.3.2.2.3.            By Disease Area

7.3.2.2.4.            By End-Use Industry

7.3.3.    United Kingdom C-reactive Protein Testing Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.            By Assay Type

7.3.3.2.2.            By Detection Range

7.3.3.2.3.            By Disease Area

7.3.3.2.4.            By End-Use Industry

7.3.4.    Italy C-reactive Protein Testing Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.            By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.            By Assay Type

7.3.4.2.2.            By Detection Range

7.3.4.2.3.            By Disease Area

7.3.4.2.4.            By End-Use Industry

7.3.5.    Spain C-reactive Protein Testing Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.            By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.            By Assay Type

7.3.5.2.2.            By Detection Range

7.3.5.2.3.            By Disease Area

7.3.5.2.4.            By End-Use Industry

8.    Asia-Pacific C-reactive Protein Testing Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Assay Type

8.2.2.    By Detection Range

8.2.3.    By Disease Area

8.2.4.    By End-Use Industry 

8.2.5.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China C-reactive Protein Testing Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.            By Assay Type

8.3.1.2.2.            By Detection Range

8.3.1.2.3.            By Disease Area

8.3.1.2.4.            By End-Use Industry

8.3.2.    India C-reactive Protein Testing Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.            By Assay Type

8.3.2.2.2.            By Detection Range

8.3.2.2.3.            By Disease Area

8.3.2.2.4.            By End-Use Industry

8.3.3.    South Korea C-reactive Protein Testing Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.            By Assay Type

8.3.3.2.2.            By Detection Range

8.3.3.2.3.            By Disease Area

8.3.3.2.4.            By End-Use Industry

8.3.4.    Japan C-reactive Protein Testing Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.            By Assay Type

8.3.4.2.2.            By Detection Range

8.3.4.2.3.            By Disease Area

8.3.4.2.4.            By End-Use Industry

8.3.5.    Australia C-reactive Protein Testing Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.            By Assay Type

8.3.5.2.2.            By Detection Range

8.3.5.2.3.            By Disease Area

8.3.5.2.4.            By End-Use Industry

9.    South America C-reactive Protein Testing Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Assay Type

9.2.2.    By Detection Range

9.2.3.    By Disease Area

9.2.4.    By End-Use Industry 

9.2.5.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil C-reactive Protein Testing Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.            By Assay Type

9.3.1.2.2.            By Detection Range

9.3.1.2.3.            By Disease Area

9.3.1.2.4.            By End-Use Industry

9.3.2.    Argentina C-reactive Protein Testing Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.            By Value 

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.            By Assay Type

9.3.2.2.2.            By Detection Range

9.3.2.2.3.            By Disease Area

9.3.2.2.4.            By End-Use Industry

9.3.3.    Colombia C-reactive Protein Testing Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.            By Value 

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.            By Assay Type

9.3.3.2.2.            By Detection Range

9.3.3.2.3.            By Disease Area

9.3.3.2.4.            By End-Use Industry

10.  Middle East and Africa C-reactive Protein Testing Market Outlook

10.1.   Market Size & Forecast         

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Assay Type

10.2.2. By Detection Range

10.2.3. By Disease Area

10.2.4. By End-Use Industry 

10.2.5. By Country

10.3.   MEA: Country Analysis

10.3.1. South Africa C-reactive Protein Testing Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Assay Type

10.3.1.2.2.         By Detection Range

10.3.1.2.3.         By Disease Area

10.3.1.2.4.         By End-Use Industry

10.3.2. Saudi Arabia C-reactive Protein Testing Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value 

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Assay Type

10.3.2.2.2.         By Detection Range

10.3.2.2.3.         By Disease Area

10.3.2.2.4.         By End-Use Industry

10.3.3. UAE C-reactive Protein Testing Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value &

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Assay Type

10.3.3.2.2.         By Detection Range

10.3.3.2.3.         By Disease Area

10.3.3.2.4.         By End-Use Industry

11.  Market Dynamics

11.1.   Drivers

11.2.   Challenges

12.  Market Trends & Developments

12.1.   Recent Developments

12.2.   Product Launches

12.3.   Mergers & Acquisitions

13.  PESTLE Analysis

14.  Porter’s Five Forces Analysis

14.1.   Competition in the Industry

14.2.   Potential of New Entrants

14.3.   Power of Suppliers

14.4.   Power of Customers

14.5.   Threat of Substitute Product

15.  Competitive Landscape

15.1.   Business Overview

15.2.   Company Snapshot

15.3.   Products & Services

15.4.   Financials (In case of listed companies)

15.5.   Recent Developments

15.6.   SWOT Analysis

15.6.1. Thermo Fisher Scientific, Inc.

15.6.2. F. Hoffmann-La Roche Ltd.

15.6.3. Danaher Corp

15.6.4. Quest Diagnostics

15.6.5. Siemens Healthineers AG

15.6.6. Abbott Laboratories Inc.

15.6.7. Merck KGaAA

15.6.8. Zoetis Inc.

15.6.9. Ortho Clinical Diagnostics

15.6.10.               Getein Biotech, Inc.

16.  Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global C-reactive Protein Testing Market was estimated to be USD 1601.01 Million in 2022.

down-arrow

Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Danaher, Quest Diagnostics, Siemens Healthineers AG, Abbott, Merck KGaAA, Zoetis, Ortho Clinical Diagnostics, Getein Biotech, Inc are some of the key players operating in the Global C-reactive Protein Testing Market.

down-arrow

Varied Reference Ranges and influence of external factors are the major challenges faced by the Global C-reactive Protein Testing Market in the upcoming years.

down-arrow

Growing Incidence of Inflammatory and Infectious Diseases and Increasing geriatric population is majorly driving the demand for the global C-reactive Protein Testing market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

C-reactive Protein Testing Market to Grow with a CAGR of 2.16% through 2028

Oct, 2023

Growing demand of Monitor the effectiveness of treatment for inflammatory conditions or cardiovascular disease are the major drivers for the Global C-reactive Protein Testing Market.

Why Choose Us